Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05371353 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05371353 · ClinicalTrials.gov record · last posted 2024-04-17

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Name: Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine — clinical trial record (NCT05371353)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseNot specified

SponsorShanghai Bovax Biotechnology Co., Ltd.

Started2022-05-14

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2022-05-07. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-04-15

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT05371353
Lead Sponsor	Shanghai Bovax Biotechnology Co., Ltd.
Conditions	HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart, CIN1, CIN2, CIN3
Enrollment	600 participants
Start Date	2022-05-14
Primary Completion	2027-05 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2024-04-17